TanyaL.RepkaMD

Oncology • Duluth, MN

Physician

Join to view full profile

Dr. Repka is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Repka's full profile

Already have an account?

Office
1608 N 28th Ave W
Duluth, MN 55806
Is this information wrong?

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1988 - 1991
Hennepin HealthcareResidency, Internal Medicine, 1986 - 1988
California Pacific Medical CenterInternship, Internal Medicine, 1984 - 1985
University of Minnesota Medical SchoolClass of 1984

Certifications & Licensure

MN State Medical License 1985 - 2024
WI State Medical License 2014 - 2017
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012
Fellow (FACP) American College of Physicians, 1996

Clinical Trials

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
Active, not recruiting
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 1996 May 01
Active, not recruiting
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Creating environment for cancer care.
Doug Abrams, Debra Bemis, Tom Gribbin, Steven Jacobson, Bruce Knepper, Rebecca Lewis, Michael P. Moran, Dianne Shanabruch, Deborah Smyth, Tanya Repka, Bob Kehoe> ;Health Facilities Management. 2008 Nov 1
14 citations
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective random...
M. Markova, Juliet N. Barker, Jeffrey S. Miller, Mukta Arora, John E. Wagner, Linda J. Burns, Margaret L. MacMillan, D Douek, Todd E. DeFor, Ye Tan, Tanya Repka, Bruce...> ;Bone Marrow Transplantation. 2007 Jan 15
21 citations
Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.
Angela R. Smith, Tanya L. Repka, Brenda J. Weigel> ;Pediatric Blood & Cancer. 2005 Nov 1
64 citations
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
Tanya Repka, Elena G. Chiorean, Katherine E. Herwig, Virginia K. Kohl, Douglas Yee, Jeffrey S. Miller> ;Clinical Cancer Research. 2003 Jul 1
179 citations
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
Linda J. Burns, Daniel J. Weisdorf, Todd E. DeFor, David H. Vesole, Tanya Repka, Bruce R. Blazar, Scott R. Burger, Angela Panoskaltsis-Mortari, Carolyn A. Keever-Taylo...> ;Bone Marrow Transplantation. 2003 Jul 1
10 citations
Penicillin-resistant Streptococcus pneumoniae septic shock and meningitis complicating chronic graft versus host disease: A case report and review of the literature
Philip A Haddad, Tanya Repka, Daniel J. Weisdorf> ;The American Journal of Medicine. 2002 Aug 1
23 citations
Evaluation of warfarin initiation regimens in elderly inpatients.
Mary Beth O'Connell, Paul Kowal, Caren J. Allivato, Tanya Repka> ;Pharmacotherapy. 2000 Aug 1
1 citations
Nonmyeloablative HPC transplantation.
Tanya Repka, Daniel J. Weisdorf> ;Transfusion. 2000 Jul 1
34 citations
Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in pat...
Linda J. Burns, Daniel J. Weisdorf, Todd E. DeFor, Tanya Repka, Kathleen M. Ogle, Cara Hummer, Jeffrey S. Miller> ;Experimental Hematology. 2000 Jan 1
165 citations
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Sarah Cooley, Linda J. Burns, Tanya Repka, Jeffrey S. Miller> ;Experimental Hematology. 1999 Oct 1
2 citations
PERIPHERAL BLOOD VERSUS BONE MARROW FOR HEMATOPOIETIC CELL TRANSPLANTATION
Tanya Repka, Daniel J. Weisdorf> ;Current Opinion in Oncology. 1998 Mar 1
70 citations
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo
Oded Shalev, Tanya Repka, Ada Goldfarb, Leonid Grinberg, Ayala Abrahamov, Nancy F. Olivieri, Eliezer A. Rachmilewitz, Robert P. Hebbel> ;Blood. 1995 Sep 1
49 citations
Nonrandom Association of Free Iron With Membranes of Sickle and β-Thalassemic Erythrocytes
Tanya Repka, Oded Shalev, Ratnammal Reddy, Jie Yuan, Ayala Abrahamov, Eliezer A. Rachmilewitz, Philip S. Low, Robert P. Hebbel> ;Blood. 1993 Nov 15
139 citations
Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes.
Mark D. Scott, J. J. M. Van Den Berg, T. Repka, Philippe Rouyer-Fessard, R. P. Hebbel, Yves Beuzard, Bertram H. Lubin> ;The Journal of Clinical Investigation. 1993 Apr 1
19 citations
Detection, characterization, and bioavailability of membrane-associated iron in the intact sickle red cell.
Takashi Sugihara, Tanya Repka, Robert P. Hebbel> ;The Journal of Clinical Investigation. 1992 Dec 1
85 citations
Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents.
Tanya Repka, Robert P. Hebbel> ;Blood. 1991 Nov 15
Reticulocytosis: defective reticulin degradation, a case report.
Repka, T., Rank, B. H.> ;Prog Clin Biol Res. 1989
Join now to see all

Grant Support

Herceptin &Il-2 For Treatment Of Her/Neu Positive CanceNational Center For Research Resources2000–2002

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Fellow

Hospital Affiliations

St. Luke's HospitalDuluth, Minnesota
Regions HospitalSaint Paul, Minnesota

TanyaL.RepkaMD

Dr. Repka is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Grant Support

Professional Memberships

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.